Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting - Seite 2
GuardantOMNI
969/10
Tumor-agnostic ctDNA monitoring in patients with metastatic HR+/HER2- breast cancer receiving first-line CDK4/6 inhibitor and endocrine therapy
Guardant Infinity
Monday, April 8 | 9:00 am – 12:30 pm
2390/5
Longitudinal assessment of circulating tumor DNA in patients with advanced colorectal cancer: A proposed general statistical framework and visualization tool
GuardantINFORM
2420/16
Evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker utilizing a tissue-free epigenomic assay in early-stage triple negative breast cancer (TNBC)
Guardant Reveal
2490/7
Quantification of tumor fraction and outcomes association in a real-world non-small cell lung cancer (NSCLC) cohort using a tissue agnostic epigenomic circulating tumor DNA (ctDNA) assay
Guardant Infinity
Monday, April 8 | 1:30 – 5:00 pm
3499/21
Non-small cell lung cancer (NSCLC) histology classification using DNA methylation data captured from liquid biopsies
Guardant Infinity
3399/1
Prediction of cardiac adverse events (AE) in trastuzumab treated breast cancer patients (pts) via a comprehensive genomic and DNA methylation blood based assay